Clinical trials: Glioblastoma Multiforme
Glioblastoma
Open Label Trial to Explore Safety of Combining Afatinib (BIBW 2992) and Radiotherapy With or Without Temozolomide in Newly Diagnosed Glioblastoma Multiform
This study is a phase I, open label trial to determine the Maximum Tolerated Dose (MTD), safety, pharmacokinetics, and efficacy of BIBW 2992 (an epidermal growth factor receptor(EGFR)inhibitor) to be used in combination with…
- Trial name
- NCT00977431
- Testing
- Temozolomide, Radiotherapy, BIBW2992
- Where
- 5 sites in United Kingdom
- Volunteers
- 36 people
- Sponsor
- Boehringer Ingelheim
Glioma, Glioma, Malignant
Assessing the Effectiveness of 2D Non-Navigated Intraoperative Ultrasound in Glioma Surgery
This retrospective study aims to assess the utility of 2D non-navigated intraoperative ultrasound (ioUS) as a cost-effective alternative for guiding the surgical resection of gliomas and for detecting residual tumor.
- Conditions
- Glioma, Glioma, Malignant, Low-grade Glioma, High-grade Glioma
- Trial name
- 2D-ioUS-Glio (NCT05873946)
- Testing
- intraoperative ultrasound
- Where
- Spain
- Volunteers
- 99 people
- Sponsor
- Hospital del Rio Hortega
Brain and Central Nervous System Tumors
Temozolomide in Treating Patients With Recurrent Malignant Glioma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of temozolomide in treating patients who have recurrent…
- Trial name
- NCT00004113
- Testing
- temozolomide
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Glioblastoma
Radiation Therapy Plus Temozolomide and Pembrolizumab With and Without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM)
Background: Glioblastoma (GBM) refers to a specific kind of brain cancer called glioblastoma. The standard treatment for GBM is radiation plus temozolomide, an oral chemotherapy drug.
- Trial name
- NCT03018288
- Testing
- Pembrolizumab, HSPPC-96, Temozolomide
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- National Cancer Institute (NCI)
Glioblastoma Multiforme, Adult
Simultaneous Integrated Boost FDOPA Positron Emission Tomography (PET) Guided in Patients With Partially- or Non-operated Glioblastoma
Glioblastoma (GBM) is the most common primary brain cancer in adults. Surgery, chemoradiotherapy (temozolomide TMZ) and then adjuvant TMZ is the standard treatment.
- Trial name
- SIB-DOPA (NCT05653622)
- Testing
- Integrated boost technique (SIB) guided by PET FDOPA
- Where
- 3 sites in France
- Volunteers
- 75 people
- Sponsor
- Centre Paul Strauss
Glioblastoma Multiforme
A Study of Temsirolimus and Bevacizumab in Recurrent Glioblastoma Multiforme
This trial is an investigator initiated, open label phase II study, where patient with recurrent primary GBM will be considered for the study.
- Trial name
- NCT00800917
- Testing
- Temsirolimus, Bevacizumab
- Where
- Denmark
- Volunteers
- 12 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Primary Brain Tumors, Metastatic Malignant Neoplasm to Brain
Study of 4-Demethyl-4-cholesteryloxycarbonylpenclome (DM-CHOC-PEN) in Patients With Brain Tumors
DM-CHOC-PEN is a polychlorinated pyridine cholesteryl carbonate that has demonstrated antineoplastic activities in patients with advanced cancers - melanoma, lung, breast and glioblastoma multiforme (GBM) involving the CNS during…
- Trial name
- DM-CHOC-PEN (NCT02038218)
- Testing
- 4-Demethyl-4-cholestryloxycarbonylpenclomedine
- Where
- 3 sites in United States
- Volunteers
- 29 people
- Sponsor
- DEKK-TEC, Inc.
Recurrent Malignant Gliomas
Study of LBH589 (Panobinostat) to Treat Malignant Brain Tumors
The drug LBH589 (panobinostat) is an experimental (investigational) drug that is being tested for recurrent (returning) malignant gliomas. An investigational drug is one that has not been approved by the U.S.
- Trial name
- NCT00848523
- Testing
- Panobinostat
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- Neurological Surgery, P.C.
Astrocytoma, Glioblastoma
CNS Penetration, PK and PD of Preoperative CC-90010 in Progressive/Recurrent Diffuse Astrocytoma, Anaplastic Astrocytoma and Glioblastoma
CC-90010-GBM-001 is a multi-center, open-label study to assess the pharmacokinetics (PK), pharmacodynamics (PD) and CNS penetration of CC-90010 following short-term interval therapy (4 daily doses ) prior to surgery, in subjects…
- Trial name
- NCT04047303
- Testing
- CC-90010
- Where
- 4 sites in United States, Spain
- Volunteers
- 20 people
- Sponsor
- Celgene
Glioblastoma (GBM)
A Phase 1/2 Study of the Safety and Tolerability of MT-125 in GBM Patients
The purpose of the study is to determine the recommended dose and further understand the safety of MT-125 in participants who have been diagnosed with glioblastoma, a primary brain tumor, when administered in combination with…
- Trial name
- STAR-GBM (NCT07185880)
- Testing
- MT-125
- Where
- 3 sites in United States
- Volunteers
- 36 people
- Sponsor
- Myosin Therapeutics Inc.
Brain Tumor - Metastatic, Brain Tumor, Adult: Glioblastoma
Comparison of Hypertonic Saline and Mannitol on Brain Relaxation During Supratentorial Tumors Resection
Hyperosmotic agents are used to decrease intracranial pressure. The aim of the study is to compare the effects of continuous 3% hypertonic saline (HS), bolus HS and 20% mannitol on intraoperative brain relaxation in patients with…
- Trial name
- NCT04314674
- Testing
- %3 HS bolus, %3 HS infusion 20 ml/h, 20% mannitol
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Istanbul University
Endometrial Neoplasms, Ovarian Neoplasms
A Study of Catequentinib Hydrochloride (AL3818) in Endometrial, LGSOC, STS or GBM Cancers
This phase 1b/2a study evaluates the investigational oral drug catequentinib hydrochloride (AL3818), given alone or with AL58805, temozolomide, or lomustine (CCNU), in adults with advanced or metastatic solid tumors.
- Conditions
- Endometrial Neoplasms, Ovarian Neoplasms, Soft Tissue Sarcoma (STS), Glioblastoma
- Trial name
- NCT07811297
- Testing
- AL58805, AL3818, Temozolomide (TMZ)
- Where
- United States
- Volunteers
- 138 people
- Sponsor
- Advenchen Pharmaceuticals, LLC.
Advanced Solid Tumors
A Study of BLZ945 Single Agent or BLZ945 in Combination With PDR001 in Advanced Solid Tumors
The purpose of this first-in-human (FIH) study of BLZ945 given as a single agent or in combination with PDR001 was to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and anti-tumor activity of…
- Trial name
- NCT02829723
- Testing
- BLZ945, PDR001
- Where
- 14 sites in United States, Israel and 6 more
- Volunteers
- 192 people
- Sponsor
- Novartis Pharmaceuticals
Brain Injury, Brain Tumor Adult
Development and Implementation of an Intervention Enhancing Involvement of Relatives to Patients With Acquired Brain Injury or Malignant Brain Tumour
Caring for a loved one with a serious illness like acquired brain injury (ABI) or primary malignant brain tumors (PMBT) can be a challenging and burdensome experience, often affecting the well-being and quality of life of…
- Conditions
- Brain Injury, Brain Tumor Adult, Traumatic Brain Injury, Glioblastoma
- Trial name
- NCT06796335
- Testing
- RIGht
- Where
- Denmark
- Volunteers
- 35 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Adult Glioblastoma, Adult Gliosarcoma
Temozolomide and Radiation Therapy With or Without Cediranib Maleate in Treating Patients With Newly Diagnosed Glioblastoma
This randomized phase II trial studies temozolomide, radiation therapy, and cediranib maleate to see how well they work compared with temozolomide, radiation therapy, and a placebo in treating patients with newly diagnosed…
- Trial name
- NCT01062425
- Testing
- 3-Dimensional Conformal Radiation Therapy, Cediranib Maleate, Intensity-Modulated Radiation Therapy
- Where
- 105 sites in United States
- Volunteers
- 261 people
- Sponsor
- National Cancer Institute (NCI)
Glioblastoma
Glioblastoma: Validation and Comparison Between Primary Tumor and Its Murine Model
Despite maximal safe surgery followed by combined chemo-radiation therapy, the outcome of patients suffering from glioblastoma (GBM) remains extremely poor with a median survival of 15 months.
- Trial name
- XENOGBM (NCT02904525)
- Testing
- 7 Tesla MRI, no contrast agent
- Where
- Switzerland
- Volunteers
- 20 people
- Sponsor
- Andreas Hottinger
Glioblastoma (GBM)
Prophylactic Regimen With Intrathecal Thiotepa in SVZ-positive or Meningeal-risk Glioblastoma
The goal of this clinical trial is to test whether adding preventive intrathecal chemotherapy (thiotepa) to the standard Stupp regimen can lower the risk of leptomeningeal metastasis (LM) and extend survival in patients with…
- Trial name
- PRISM (NCT07511725)
- Testing
- Maximal surgical resection, Concomitant Chemoradiotherapy (Stupp backbone), Preventive Intrathecal Thiotepa
- Where
- China
- Volunteers
- 38 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Brain and Central Nervous System Tumors
Radiation Therapy Plus Hyperbaric Oxygen in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Hyperbaric oxygen may increase the effectiveness of radiation therapy.
- Trial name
- NCT00006460
- Testing
- hyperbaric oxygen, radiation therapy
- Where
- United States
- Sponsor
- Barrett Cancer Center
High Grade Glioma
Antineoplaston Therapy in Treating Children With Recurrent or Refractory High-Grade Glioma
RATIONALE: Current therapies for children with recurrent/progressive high grade gliomas provide very limited benefit to the patient.
- Trial name
- NCT00003535
- Testing
- Antineoplaston therapy (Atengenal + Astugenal)
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Burzynski Research Institute
Glioblastoma, Gliosarcoma
Study of ABBV-637 or ABBV-155 With ERAS-801 for People With Glioblastoma
The researchers are doing this study to find out whether the drugs ABBV-637 and ABBV-155 are safe treatments that cause few or mild side effects when given alone or in combination with ERAS-801 in people with recurrent GBM.
- Trial name
- NCT06934889
- Testing
- ERAS-801, ABBV-637, ABBV-155
- Where
- 11 sites in United States
- Volunteers
- 60 people
- Sponsor
- Memorial Sloan Kettering Cancer Center